Eric Blanc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric Blanc has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
- Dieter Beule
Charité Universitätsmedizin Berlin, Germany (O.O., E.B., A.I., D.B., H.G.).
14 shared publications - Thomas Blankenstein
Molecular Immunology and Gene Therapy, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
8 shared publications - Amin Ben-Hamza
Department of Hematology, Oncology, and Tumor Immunology, Charit e-Universit€ atsmedizin Berlin, Corporate Member of Freie Universit€ at Berlin and
7 shared publications - Andreas Moosmann
Department of Medicine III, Klinikum der Universit€ at M€ unchen, Munich, Germany
7 shared publications - Armin Gerbitz
Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada
7 shared publications - Carlotta Welters
Department of Hematology, Oncology, and Tumor Immunology, Charit e-Universit€ atsmedizin Berlin, Corporate Member of Freie Universit€ at Berlin and
7 shared publications
Latest Publications
- Open Access
- 3 October 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 30694
Proteome signatures in ICU patients with COVID-19 and acute brain dysfunction: an observational cohort study
Deep sedation and delirium are common in COVID-19 intensive care unit (ICU) patients. Biomarkers for prediction, detection, and monitoring are missing. Unbiased omics analyses are warranted to gain a systems biology view on pathophysiology. This prospective observational satellite study analysed the proteome signatures of COVID-19 ICU patients with and without acute brain dysfunction (ABD). Conducted in university hospital ICUs between March 2020 and September 2021, patients of legal age with a positive SARS-CoV-2 test were screened daily for deep sedation and delirium. Blood samples were taken thrice weekly. In total, 457 samples were analysed using data-independent acquisition mass spectrometry to determine protein levels. A mixed-effects regression model was developed to identify proteins significantly influenced by ABD, accounting for sex, age and illness severity as confounders. This model also aimed to determine proteins that were either up- or downregulated in association with ABD. Additionally, an enrichment analysis was conducted to examine the biological pathways linked to these ABD-associated proteins. Among 360 patients, 69 were analysed for protein profiling; 42 (60.9%) had ABD at ICU admission [deep sedation: (33; 47,8%); delirium (9; 13%)]. Of 204 proteins, deep sedation markedly shaped the proteomic profile, with 23 proteins uniquely distinguishing it from delirium and no ABD, and 21 proteins were shared across both ABD states. Four proteins (SERPINF1, C1QB, C1QC, PPBP) were specific to delirium, while three (GSN, C1S, PON1) differed across all groups. APOC3 displayed a distinct gradient, highest in delirium and lowest in deep sedation. Pathways involved coagulation, immune response, and lipid metabolism: deep sedation was characterized by complement and coagulation signatures, whereas delirium was also linked to lipid-related processes. The enrichment pathway analysis revealed “Network map of SARS-CoV-2 signalling” (M42569/WP5115) in deep sedation, and “Homeostatic process” (M17351) in delirium. We identified proteomic signatures in COVID-19 ICU patients with ABD, including up- and downregulated proteins. These findings may provide potential biomarker candidates for the assessment of ABD risk and its underlying causes. They could represent a further step towards the development of personalized, causative treatments for delirium and its monitoring in the ICU. Trial registration: The study was retrospectively registered in the German Clinical Trials Register (DRKS00021688 May 13, 2020).
- 3 October 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 30694
Open AccessProteome signatures in ICU patients with COVID-19 and acute brain dysfunction: an observational cohort study
Deep sedation and delirium are common in COVID-19 intensive care unit (ICU) patients. Biomarkers for prediction, detection, and monitoring are missing. Unbiased omics analyses are warranted to gain a systems biology view on pathophysiology. This prospective observational satellite study analysed the proteome signatures of COVID-19 ICU patients with and without acute brain dysfunction (ABD). Conducted in university hospital ICUs between March 2020 and September 2021, patients of legal age with a positive SARS-CoV-2 test were screened daily for deep sedation and delirium. Blood samples were taken thrice weekly. In total, 457 samples were analysed using data-independent acquisition mass spectrometry to determine protein levels. A mixed-effects regression model was developed to identify proteins significantly influenced by ABD, accounting for sex, age and illness severity as confounders. This model also aimed to determine proteins that were either up- or downregulated in association with ABD. Additionally, an enrichment analysis was conducted to examine the biological pathways linked to these ABD-associated proteins. Among 360 patients, 69 were analysed for protein profiling; 42 (60.9%) had ABD at ICU admission [deep sedation: (33; 47,8%); delirium (9; 13%)]. Of 204 proteins, deep sedation markedly shaped the proteomic profile, with 23 proteins uniquely distinguishing it from delirium and no ABD, and 21 proteins were shared across both ABD states. Four proteins (SERPINF1, C1QB, C1QC, PPBP) were specific to delirium, while three (GSN, C1S, PON1) differed across all groups. APOC3 displayed a distinct gradient, highest in delirium and lowest in deep sedation. Pathways involved coagulation, immune response, and lipid metabolism: deep sedation was characterized by complement and coagulation signatures, whereas delirium was also linked to lipid-related processes. The enrichment pathway analysis revealed “Network map of SARS-CoV-2 signalling” (M42569/WP5115) in deep sedation, and “Homeostatic process” (M17351) in delirium. We identified proteomic signatures in COVID-19 ICU patients with ABD, including up- and downregulated proteins. These findings may provide potential biomarker candidates for the assessment of ABD risk and its underlying causes. They could represent a further step towards the development of personalized, causative treatments for delirium and its monitoring in the ICU. Trial registration: The study was retrospectively registered in the German Clinical Trials Register (DRKS00021688 May 13, 2020).
- Open Access
- 26 December 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (3)
FOXO1 re-expression with a dual-recombinase allele rescues class switching in germinal center B cells
Modeling complex (patho)physiological processes by sequential targeted mutagenesis in mice is limited by the lack of precision of cellular targeting and complex breeding strategies. We present a new Cre/DreERT2 dual-recombinase germinal center B cell (GCBC)–specific strain, with co-expression of the recombinases from a single allele. This enables highly efficient Cre-mediated FOXO1 knockout in GCBCs in vivo, followed by time-controlled, efficient Dre-mediated FOXO1 re-expression in the same cells, leading to functional rescue of GC compartmentalization and class switch recombination. The present approach can be easily adapted to other cellular contexts.
- 26 December 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (3)
Open AccessFOXO1 re-expression with a dual-recombinase allele rescues class switching in germinal center B cells
Modeling complex (patho)physiological processes by sequential targeted mutagenesis in mice is limited by the lack of precision of cellular targeting and complex breeding strategies. We present a new Cre/DreERT2 dual-recombinase germinal center B cell (GCBC)–specific strain, with co-expression of the recombinases from a single allele. This enables highly efficient Cre-mediated FOXO1 knockout in GCBCs in vivo, followed by time-controlled, efficient Dre-mediated FOXO1 re-expression in the same cells, leading to functional rescue of GC compartmentalization and class switch recombination. The present approach can be easily adapted to other cellular contexts.
- 22 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (896) , eadr3738
Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer
Therapy-induced acquired resistance limits the clinical effectiveness of mutation-specific KRAS inhibitors in colorectal cancer (CRC). Here, we investigated whether broad-spectrum, active-state RAS inhibitors meet similar limitations. We found that KRAS-mutant CRC cell lines were sensitive to the RAS(ON) multiselective RAS inhibitor RMC-7977, given that treatment resulted in RAS-RAF-MEK-ERK pathway inhibition; halted proliferation; and, in some cases, induced apoptosis. RMC-7977 initially reduced the activity of a compartment-specific, dual-color reporter of ERK activity, with reporter reactivation emerging after long-term dose escalation. These drug-resistant cell populations exhibited distinct patterns of phospho-protein abundance, transcriptional activities, and genomic mutations, including a Y71H mutation in KRAS and an S257L mutation in RAF1. Transgenic expression of KRAS G13D, Y71H or RAF1 S257L in drug-sensitive CRC cells induced resistance to RMC-7977. CRC cells that were resistant to RMC-7977 and harboring RAF1 S257L exhibited synergistic sensitivity to concurrent inhibition of RAS and RAF. Our findings demonstrate the power of reporter-assisted screening together with single-cell analyses for dissecting the complex landscape of therapy resistance. The strategy offers opportunities to develop clinically relevant combinatorial treatments to counteract the emergence of resistant cancer cells.
- 22 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (896) , eadr3738
Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibitors in colorectal cancer
Therapy-induced acquired resistance limits the clinical effectiveness of mutation-specific KRAS inhibitors in colorectal cancer (CRC). Here, we investigated whether broad-spectrum, active-state RAS inhibitors meet similar limitations. We found that KRAS-mutant CRC cell lines were sensitive to the RAS(ON) multiselective RAS inhibitor RMC-7977, given that treatment resulted in RAS-RAF-MEK-ERK pathway inhibition; halted proliferation; and, in some cases, induced apoptosis. RMC-7977 initially reduced the activity of a compartment-specific, dual-color reporter of ERK activity, with reporter reactivation emerging after long-term dose escalation. These drug-resistant cell populations exhibited distinct patterns of phospho-protein abundance, transcriptional activities, and genomic mutations, including a Y71H mutation in KRAS and an S257L mutation in RAF1. Transgenic expression of KRAS G13D, Y71H or RAF1 S257L in drug-sensitive CRC cells induced resistance to RMC-7977. CRC cells that were resistant to RMC-7977 and harboring RAF1 S257L exhibited synergistic sensitivity to concurrent inhibition of RAS and RAF. Our findings demonstrate the power of reporter-assisted screening together with single-cell analyses for dissecting the complex landscape of therapy resistance. The strategy offers opportunities to develop clinically relevant combinatorial treatments to counteract the emergence of resistant cancer cells.
- Open Access
Unique proteome signatures in ICU patients with COVID-19 and delirium: an observational study
Background Delirium is common in COVID-19 intensive care unit (ICU) patients. Biomarkers for prediction, detection, and monitoring are missing. Unbiased omics analyses are warranted to gain a systems biology view on pathophysiology. Methods This prospective observational satellite study aims to investigate the proteome signatures of COVID-19 ICU patients, comparing those with delirium to those without. This study was conducted in ICUs of a university hospital between March 2020 and September 2021. ICU patients of legal age with a positive SARS-CoV-2 test were screened daily for oversedation and delirium. Blood samples were taken thrice a week. 457 samples were analyzed using data-independent acquisition mass spectrometry to determine protein levels. A mixed-effects logistic regression model was developed to identify proteins significantly influenced by delirium, accounting for sex and age as confounders. This model also aimed to determine proteins that were either up- or downregulated in association with delirium. Additionally, an enrichment analysis was conducted to examine the biological pathways linked to these delirium-associated proteins. Results Out of 360 ICU patients, 69 were analyzed for protein profiling. Out of these 69 patients, 42 patients (60.9%) had delirium on ICU admission, and 27 (39.1%) did not. Based on the multivariate model, the analysis of 204 proteins unfolded 125 (61.3%) to be differentially expressed. In total, 80.8% (n=101) of these 125 proteins were associated with delirium. Of these, 10 proteins were uniquely associated with delirium and were not significant in the multivariate model (SERPING1, SERPINA7, HP, TGFBI, CD5L, IGHV3-7, IGHV1-46, IGHV3-15, IGHV3-23, and “IGHV4-34;IGHV4-38-2”). In the univariate model for delirium, six out of 111 significant proteins showed increased expression with a log2FC > 0.5: PIGR, MST1, LBP, CRP, SAA1, and “SAA1;SAA2”; while three showed decreased expression with a log2FC < - 0.5: HP, PPBP, and “HP;HPR”. The enrichment analysis of delirium-influenced proteins revealed three significant pathways: “Network map of SARS-CoV-2 signaling” (M42569/WP5115), “Acute inflammatory response” (M10617), and “Regulation of defense response” (M15277). Conclusion We identified a unique proteomic signature in COVID-19 ICU patients with delirium, including up- and downregulated proteins. These findings may provide potential biomarker candidates for the assessment of delirium risk and its underlying causes. These findings could be a further step towards the development of personalized, causative treatments for delirium and its monitoring in the ICU. Trial registration The study was retrospectively registered in the German Clinical Trials Register on May 13, 2020 (DRKS00021688).
Open AccessUnique proteome signatures in ICU patients with COVID-19 and delirium: an observational study
Background Delirium is common in COVID-19 intensive care unit (ICU) patients. Biomarkers for prediction, detection, and monitoring are missing. Unbiased omics analyses are warranted to gain a systems biology view on pathophysiology. Methods This prospective observational satellite study aims to investigate the proteome signatures of COVID-19 ICU patients, comparing those with delirium to those without. This study was conducted in ICUs of a university hospital between March 2020 and September 2021. ICU patients of legal age with a positive SARS-CoV-2 test were screened daily for oversedation and delirium. Blood samples were taken thrice a week. 457 samples were analyzed using data-independent acquisition mass spectrometry to determine protein levels. A mixed-effects logistic regression model was developed to identify proteins significantly influenced by delirium, accounting for sex and age as confounders. This model also aimed to determine proteins that were either up- or downregulated in association with delirium. Additionally, an enrichment analysis was conducted to examine the biological pathways linked to these delirium-associated proteins. Results Out of 360 ICU patients, 69 were analyzed for protein profiling. Out of these 69 patients, 42 patients (60.9%) had delirium on ICU admission, and 27 (39.1%) did not. Based on the multivariate model, the analysis of 204 proteins unfolded 125 (61.3%) to be differentially expressed. In total, 80.8% (n=101) of these 125 proteins were associated with delirium. Of these, 10 proteins were uniquely associated with delirium and were not significant in the multivariate model (SERPING1, SERPINA7, HP, TGFBI, CD5L, IGHV3-7, IGHV1-46, IGHV3-15, IGHV3-23, and “IGHV4-34;IGHV4-38-2”). In the univariate model for delirium, six out of 111 significant proteins showed increased expression with a log2FC > 0.5: PIGR, MST1, LBP, CRP, SAA1, and “SAA1;SAA2”; while three showed decreased expression with a log2FC < - 0.5: HP, PPBP, and “HP;HPR”. The enrichment analysis of delirium-influenced proteins revealed three significant pathways: “Network map of SARS-CoV-2 signaling” (M42569/WP5115), “Acute inflammatory response” (M10617), and “Regulation of defense response” (M15277). Conclusion We identified a unique proteomic signature in COVID-19 ICU patients with delirium, including up- and downregulated proteins. These findings may provide potential biomarker candidates for the assessment of delirium risk and its underlying causes. These findings could be a further step towards the development of personalized, causative treatments for delirium and its monitoring in the ICU. Trial registration The study was retrospectively registered in the German Clinical Trials Register on May 13, 2020 (DRKS00021688).
- Open Access
- 19 July 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (9) , 1655-1669
High‐confidence calling of normal epithelial cells allows identification of a novel stem‐like cell state in the colorectal cancer microenvironment
Single‐cell analyses can be confounded by assigning unrelated groups of cells to common developmental trajectories. For instance, cancer cells and admixed normal epithelial cells could adopt similar cell states thus complicating analyses of their developmental potential. Here, we develop and benchmark CCISM (for Cancer Cell Identification using Somatic Mutations) to exploit genomic single nucleotide variants for the disambiguation of cancer cells from genomically normal non‐cancer cells in single‐cell data. We find that our method and others based on gene expression or allelic imbalances identify overlapping sets of colorectal cancer versus normal colon epithelial cells, depending on molecular characteristics of individual cancers. Further, we define consensus cell identities of normal and cancer epithelial cells with higher transcriptome cluster homogeneity than those derived using existing tools. Using the consensus identities, we identify significant shifts of cell state distributions in genomically normal epithelial cells developing in the cancer microenvironment, with immature states increased at the expense of terminal differentiation throughout the colon, and a novel stem‐like cell state arising in the left colon. Trajectory analyses show that the new cell state extends the pseudo‐time range of normal colon stem‐like cells in a cancer context. We identify cancer‐associated fibroblasts as sources of WNT and BMP ligands potentially contributing to increased plasticity of stem cells in the cancer microenvironment. Our analyses advocate careful interpretation of cell heterogeneity and plasticity in the cancer context and the consideration of genomic information in addition to gene expression data when possible.
- 19 July 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (9) , 1655-1669
Open AccessHigh‐confidence calling of normal epithelial cells allows identification of a novel stem‐like cell state in the colorectal cancer microenvironment
Single‐cell analyses can be confounded by assigning unrelated groups of cells to common developmental trajectories. For instance, cancer cells and admixed normal epithelial cells could adopt similar cell states thus complicating analyses of their developmental potential. Here, we develop and benchmark CCISM (for Cancer Cell Identification using Somatic Mutations) to exploit genomic single nucleotide variants for the disambiguation of cancer cells from genomically normal non‐cancer cells in single‐cell data. We find that our method and others based on gene expression or allelic imbalances identify overlapping sets of colorectal cancer versus normal colon epithelial cells, depending on molecular characteristics of individual cancers. Further, we define consensus cell identities of normal and cancer epithelial cells with higher transcriptome cluster homogeneity than those derived using existing tools. Using the consensus identities, we identify significant shifts of cell state distributions in genomically normal epithelial cells developing in the cancer microenvironment, with immature states increased at the expense of terminal differentiation throughout the colon, and a novel stem‐like cell state arising in the left colon. Trajectory analyses show that the new cell state extends the pseudo‐time range of normal colon stem‐like cells in a cancer context. We identify cancer‐associated fibroblasts as sources of WNT and BMP ligands potentially contributing to increased plasticity of stem cells in the cancer microenvironment. Our analyses advocate careful interpretation of cell heterogeneity and plasticity in the cancer context and the consideration of genomic information in addition to gene expression data when possible.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Supplementary Figure from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Supplementary Figure from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Supplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Supplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Multiple myeloma is a hematologic malignancy of monoclonal plasma cells that accumulate in the bone marrow. Despite their clinical and pathophysiologic relevance, the roles of bone marrow–infiltrating T cells in treatment-naïve patients are incompletely understood. We investigated whether clonally expanded T cells (i) were detectable in multiple myeloma bone marrow, (ii) showed characteristic immune phenotypes, and (iii) whether dominant clones recognized antigens selectively presented on multiple myeloma cells. Single-cell index sorting and T-cell receptor (TCR) αβ sequencing of bone marrow T cells from 13 treatment-naïve patients showed dominant clonal expansion within CD8+ cytolytic effector compartments, and only a minority of expanded T-cell clones expressed the classic immune-checkpoint molecules PD-1, CTLA-4, or TIM-3. To identify their molecular targets, TCRs of 68 dominant bone marrow clones from five selected patients were reexpressed and incubated with multiple myeloma and non–multiple myeloma cells from corresponding patients. Only 1 of 68 TCRs recognized antigen presented on multiple myeloma cells. This TCR was HLA-C–restricted, self-peptide–specific and could be activated by multiple myeloma cells of multiple patients. The remaining dominant T-cell clones did not recognize multiple myeloma cells and were, in part, specific for antigens associated with chronic viral infections. In conclusion, we showed that dominant bone marrow T-cell clones in treatment-naïve patients rarely recognize antigens presented on multiple myeloma cells and exhibit low expression of classic immune-checkpoint molecules. Our data provide experimental context for experiences from clinical immune-checkpoint inhibition trials and will inform future T cell–dependent therapeutic strategies.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Multiple myeloma is a hematologic malignancy of monoclonal plasma cells that accumulate in the bone marrow. Despite their clinical and pathophysiologic relevance, the roles of bone marrow–infiltrating T cells in treatment-naïve patients are incompletely understood. We investigated whether clonally expanded T cells (i) were detectable in multiple myeloma bone marrow, (ii) showed characteristic immune phenotypes, and (iii) whether dominant clones recognized antigens selectively presented on multiple myeloma cells. Single-cell index sorting and T-cell receptor (TCR) αβ sequencing of bone marrow T cells from 13 treatment-naïve patients showed dominant clonal expansion within CD8+ cytolytic effector compartments, and only a minority of expanded T-cell clones expressed the classic immune-checkpoint molecules PD-1, CTLA-4, or TIM-3. To identify their molecular targets, TCRs of 68 dominant bone marrow clones from five selected patients were reexpressed and incubated with multiple myeloma and non–multiple myeloma cells from corresponding patients. Only 1 of 68 TCRs recognized antigen presented on multiple myeloma cells. This TCR was HLA-C–restricted, self-peptide–specific and could be activated by multiple myeloma cells of multiple patients. The remaining dominant T-cell clones did not recognize multiple myeloma cells and were, in part, specific for antigens associated with chronic viral infections. In conclusion, we showed that dominant bone marrow T-cell clones in treatment-naïve patients rarely recognize antigens presented on multiple myeloma cells and exhibit low expression of classic immune-checkpoint molecules. Our data provide experimental context for experiences from clinical immune-checkpoint inhibition trials and will inform future T cell–dependent therapeutic strategies.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Supplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Supplementary Data from Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma